{"id":"drug-ac-170-0-24","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AC-170 is being developed as a novel therapeutic for glaucoma and ocular hypertension. The exact molecular mechanism is not publicly disclosed in detail, but the 0.24% concentration formulation suggests a topical eye drop designed to modulate intraocular pressure through one or more pathways affecting aqueous humor dynamics.","oneSentence":"AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:05.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT01495338","phase":"PHASE1","title":"A Comparison of the Safety and Comfort of AC-170","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-12","conditions":"Normal Ocular Health","enrollment":60},{"nctId":"NCT02132169","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Safety of AC-170 0.24%","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2014-05","conditions":"Atopic Disease (Including Allergic Conjunctivitis)","enrollment":512}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["1 drop in each eye 2 times daily for up to 6 weeks"],"phase":"phase_3","status":"active","brandName":"Drug: AC-170 0.24%","genericName":"Drug: AC-170 0.24%","companyName":"Aciex Therapeutics, Inc.","companyId":"aciex-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}